Alzheimer's Disease International (ADI)
News, blogs and stories from across the field of dementia, the work of Alzheimer’s Disease International and our members.
ADI is pleased to introduce the new blog series entitled ‘From Where I Sit’, which highlights the reflections and thoughts of ADI CEO, Dr Faith Mwangi-Powell on how we can shape the further of Alzheimer’s and dementia policy, prevention, treatment and care.
Read the highlights for the 2026 World Alzheimer's Month campaign, from ADI member activities to key events and achievements from the wider community of advocates united under the theme of ‘The Earlier You Know, The More You Can Do: A Dementia Diagnosis Matters’.
As the World Alzheimer’s Month 2024 campaign draws to close, ADI is proud to report on this year’s achievements from our global community as we united to focus on the urgent message: "Time to act on dementia." With over 81 million global impressions and 4,000 mentions in the media, the campaign brought together dementia associations, advocates, professionals, and carers to raise awareness and reduce stigma to hold events worldwide, including memory walks, exhibitions, presentations, and illuminated landmarks that highlighted the importance of addressing dementia stigma. To all that have taken part, we would like to say thank you for another World Alzheimer’s Month filled with global action.
ADI is sharing a round-up of the recent activities in the Americas region during this year’s World Alzheimer’s Month. Our member associations in the Americas have showcased their collective strength in the region while making strides in both their dementia awareness-raising efforts as well as their support for those who have been impacted by dementia and their carers.
The UK medicines regulator, the Medicines and Healthcare products Regulatory Agency (MHRA) has approved the marketing authorisation for lecanemab in the treatment of early Alzheimer’s disease. However, the treatment will not be available through the National Health Service (NHS), the UK’s publicly funded health agency.
ADI’s Diego Aguilar and Nick House attend the Alzheimer's Association International Conference in Philadelphia (USA), delivering key insights, conducting vital meetings and advocating for care in the era of new treatments.
The research, commissioned by The Lancet revised their 2020 findings to include failing eyesight and high LDL cholesterol as risk factors for dementia.
Lecanemab represents the second antibody treatment for Alzheimer’s disease to not be recommended marketing authorisation by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).
On 2 July 2024, the U.S. Food and Drug Administration (FDA) approved the marketing authorisation for Kisunla (donanemab) for adults with early symptomatic Alzheimer’s disease (AD), which includes mild cognitive impairment (MCI) or the mild dementia stage of Alzheimer’s disease. Donanemab is the…
Regional Director for the Americas, Diego Aguilar, alongside politician and neuroscientist Facundo Manes, and ADI’s Argentinian member association A.L.M.A, joined for urgent action on dementia following steeply increasing dementia forecasts and stalling progress towards a National Dementia Plan in the country.